About: Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.53 (-7.83%)
VRCA NASDAQ Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc share price
Atividade de preço de VRCA
Último preço
$ 3,530
Variação (24h)
-0,30 USD (7,83%)
Volume
20.67K
Volume (média 4 sem.)
-
Abertura
$ 3,75
Variação do dia
$ 3,40 - $ 3,75
Fechamento anterior
$ 3,83
Último negócio
23 Oct, 8:00 pm GMT+0
Atrasado
23 Oct, 8:00 pm GMT+0
VRCA price performance
Atrasado
23 Oct, 8:00 pm GMT+0
quote.marketSignals